Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model. 2007

Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Shiga, Japan 520-2192.

OBJECTIVE To evaluate the role of transient receptor potential vanilloid 1 (TRPV1) in a rat hemorrhagic shock (HS) model using the TRPV1 antagonist, capsazepine (CPZ). BACKGROUND TRPV1, distributed within the sensory nerve, plays a role in the regulation of cardiovascular functions. TRPV1 may be involved in the cardiovascular responses to HS. METHODS Male rats were anesthetized and HS was induced with the mean arterial pressure (MAP) at 30 mm Hg for 90 minutes. CPZ (5.0 micromol/kg) was administered at 30 minutes after the shock induction, and the 24-hour survival rates were assessed. The MAP, heart rate, and shed blood volume (SBV) were recorded throughout the experiment. Arterial blood gas analysis and the plasma catecholamines levels were measured before and after HS. Double-immunohistochemistry for Fos and tyrosine hydroxylase (TH) was performed in the rostral ventrolateral medulla (RVLM) of the brain. RESULTS CPZ significantly improved the 24-hour survival rates, which was accompanied by the increase in the MAP and the SBV, a decrease of the plasma catecholamines levels, and attenuation of the severe metabolic acidosis. Furthermore, CPZ reduced the percentage of double-labeled neurons for Fos and TH in the RVLM of the rat brain. CONCLUSIONS TRPV1 may be involved in the regulation of the cardiovascular responses to HS, at least in part, by recruiting catecholaminergic neurons in the RVLM. CPZ appears to induce metabolic compensations, which may be potentially useful in HS.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D008297 Male Males
D002211 Capsaicin An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS. 8-Methyl-N-Vanillyl-6-Nonenamide,Antiphlogistine Rub A-535 Capsaicin,Axsain,Capsaicine,Capsicum Farmaya,Capsidol,Capsin,Capzasin,Gelcen,Katrum,NGX-4010,Zacin,Zostrix,8 Methyl N Vanillyl 6 Nonenamide,NGX 4010,NGX4010
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012771 Shock, Hemorrhagic Acute hemorrhage or excessive fluid loss resulting in HYPOVOLEMIA. Hemorrhagic Shock
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
November 2016, Basic & clinical pharmacology & toxicology,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
November 2010, British journal of anaesthesia,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
May 1997, Neuroscience letters,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
July 2005, European journal of pharmacology,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
August 1993, Surgery,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
August 2022, Experimental animals,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
April 2011, Biomedical chromatography : BMC,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
August 2021, Life sciences,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
April 2008, CNS & neurological disorders drug targets,
Hiroya Akabori, and Hiroshi Yamamoto, and Hiroshi Tsuchihashi, and Tsuyoshi Mori, and Kazunori Fujino, and Tomoharu Shimizu, and Yoshihiro Endo, and Tohru Tani
November 2006, Gut,
Copied contents to your clipboard!